Stoke Therapeutics (STOK) Non-Current Assets (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Non-Current Assets of $76.6 million for Q1 2026, up 145.88% year-over-year from $31.2 million in Q1 2025, and down 32.06% quarter-over-quarter from $112.7 million in Q4 2025.
Stoke Therapeutics (STOK) Non-Current Assets (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $76.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 145.88% year-over-year to $76.6 million; the TTM figure through Mar 2026 stood at $391.7 million (up 225.27% YoY), while the FY2025 annual figure was $112.7 million, up 190.56% from the prior year.
- Non-Current Assets for Q1 2026 stood at $76.6 million, down from $112.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $114.5 million in Q2 2025, with the low at $9.9 million in Q3 2023.
- The 5-year median for Non-Current Assets is $13.0 million (2023), against an average of $36.3 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets declined 24.22% in 2023, then surged 964.18% in 2025.
- Stoke Therapeutics' Non-Current Assets stood at $12.0 million in 2022, then climbed by 8.39% to $13.0 million in 2023, then jumped by 198.38% to $38.8 million in 2024, then surged by 190.56% to $112.7 million in 2025, then tumbled by 32.06% to $76.6 million in 2026.
- Business Quant data shows STOK's Non-Current Assets at $76.6 million in Q1 2026, $112.7 million in Q4 2025, and $87.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 71.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.43 Mn |
| Mar 31, 2026 | 76.60 Mn |
| Dec 31, 2025 | 112.73 Mn |
| Sep 30, 2025 | 87.83 Mn |
| Jun 30, 2025 | 114.54 Mn |
| Mar 31, 2025 | 31.15 Mn |
| Dec 31, 2024 | 38.80 Mn |
| Sep 30, 2024 | 39.71 Mn |
| Jun 30, 2024 | 10.76 Mn |
| Mar 31, 2024 | 11.91 Mn |
| Dec 31, 2023 | 13.00 Mn |
| Sep 30, 2023 | 9.87 Mn |
| Jun 30, 2023 | 10.69 Mn |
| Mar 31, 2023 | 11.56 Mn |
| Dec 31, 2022 | 12.00 Mn |
| Sep 30, 2022 | 13.03 Mn |
| Jun 30, 2022 | 12.27 Mn |
| Mar 31, 2022 | 10.17 Mn |
| Dec 31, 2021 | 9.65 Mn |
| Sep 30, 2021 | 8.84 Mn |